Abstract:
This study investigated the effect of dapagliflozin on the neovascularization of carotid atherosclerotic plaques in patients with type 2 diabetes mellitus (T2DM) who failed to meet the initial treatment standard of metformin. Sixty patients with HbA1c 7.0-11.0% after metformin (2000 mg/day) treatment were included and randomized into two groups: group A (dapagliflozin) and group B (glimepiride). After 12 weeks of treatment, group A had lower mean blood glucose (MBG) and higher time in range (TIR) compared to group B. After 48 weeks of treatment, group A showed significant differences in various indicators compared to group B, including lower MBG, higher TIR, lower fasting insulin (FINS), improved insulin resistance, reduced systolic blood pressure (SBP), and lower BMI, waist-to-hip ratio (WHR) and time intensity curve of carotid angiography. No statistical differences in HbA1c, fasting blood glucose (FBG), diastolic blood pressure, low-density lipoprotein cholesterol (LDL), ALT, AST, blood urea nitrogen (BUN), serum creatinine or glomerular filtration rate (eGFR) after 12- and 48-week treatment between either group. Dapagliflozin treatment in T2DM patients can effectively control blood glucose, improve insulin resistance, reduce SBP, lower BMI and WHR, and improve the time intensity curve of carotid angiography, delaying the progress of diabetic macrovascular complications.
Keywords:
type 2 diabetes
,
Dapagliflozin
,
Carotid atherosclerosis
,
macrovascular complications